We are pleased to learn that Acadia Pharmaceuticals Canada, the manufacturer of DAYBUE, has successfully secured an agreement with a major private insurer to have DAYBUE listed as an eligible treatment under some insurance plans.

This marks the first time that eligible patients in Canada can receive insured access to DAYBUE for Rett Syndrome.

As you likely know, private insurance plans are unique to each employer, so while some plans may provide coverage for DAYBUE, others may not. Access is based on eligibility and individual coverage.

Acadia provides support to navigate these insurance plans through their patient support program, Acadia Connect. Once enrolled in the program, the team can provide patients and caregivers with support to navigate potential coverage for DAYBUE under their specific plan. 

We encourage all patients and caregivers interested in trying DAYBUE to speak with their physician to discuss enrolment in the program. For more information, visit https://acadiaconnect.ca/.

For those that are already enrolled in the program, you can expect to receive a call from the program in the coming weeks if your loved one is now eligible.

We are encouraged by this recent development and remain committed to advocating for broader coverage for DAYBUE, under both public and private insurance plans.